Loading
GREM1 (Gremlin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.
Cytokine that may play an important role during carcinogenesis and metanephric kidney organogenesis, as a BMP antagonist required for early limb outgrowth and patterning in maintaining the FGF4-SHH feedback loop. Down-regulates the BMP4 signalling in a dose-dependent manner. Antagonist of BMP2; inhibits BMP2-mediated differentiation of osteoblasts (in vitro).
Open Targets scores its association with cancer at 0.56 (direct and indirect evidence; datatypes literature 0.98, animal model 0.38, genetic association 0.70).
In plain words · GREM1 (Gremlin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.
GREM1 (Gremlin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.
Cytokine that may play an important role during carcinogenesis and metanephric kidney organogenesis, as a BMP antagonist required for early limb outgrowth and patterning in maintaining the FGF4-SHH feedback loop.
1 product aims at GREM1: antibodies. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
First described 1998. Earliest sequence paper UniProt cites for the protein: Hsu D.R. et al, Mol. Cell, 1998, "The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities". Source.
Sources: HGNC HGNC:2001 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O60565 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000166923 (association with cancer (MONDO_0004992) 0.56; per-cancer scores at or above 0.5: colorectal cancer 0.56 (GraphQL API, CC0))
Cytokine that may play an important role during carcinogenesis and metanephric kidney organogenesis, as a BMP antagonist required for early limb outgrowth and patterning in maintaining the FGF4-SHH feedback loop. Down-regulates the BMP4 signalling in a dose-dependent manner. Antagonist of BMP2; inhibits BMP2-mediated differentiation of osteoblasts (in vitro). Acts as inhibitor of monocyte chemotaxis. Can inhibit the growth or viability of normal cells but not transformed cells when is overexpressed. Location: Secreted (UniProt). Locus 15q13.3 (HGNC).
TST003 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for colorectal cancer.
Query for this target: (TITLE:"GREM1" OR ABSTRACT:"GREM1" OR TITLE:"gremlin 1, DAN family BMP antagonist" OR ABSTRACT:"gremlin 1, DAN family BMP antagonist" OR TITLE:"Gremlin-1" OR ABSTRACT:"Gremlin-1" OR TITLE:"gremlin" OR ABSTRACT:"gremlin" OR TITLE:"DAND2" OR ABSTRACT:"DAND2" OR TITLE:"CKTSF1B1" OR ABSTRACT:"CKTSF1B1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GREM1, not a curated reading list.